Immix Biopharma(US:IMMX) Globenewswire·2025-11-03 13:45Core Insights - Immix Biopharma, Inc. announced that interim results from its Phase 1/2 NXC-201 NEXICART-2 trial in relapsed/refractory AL Amyloidosis will be presented at ASH 2025 [2][3] Company Overview - Immix Biopharma is recognized as the global leader in relapsed/refractory AL Amyloidosis, a severe disease characterized by the immune system producing toxic light chains that lead to organ failure [4][8] - The company’s lead candidate, NXC-201, is a CAR-T cell therapy designed to target BCMA and has received both Regenerative Medicine Advanced Therapy (RMAT) and Orphan Drug Designation from the FDA [6][8] Clinical Trial Information - The NEXICART-2 trial is an ongoing multi-site Phase 1/2 clinical study of NXC-201, which aims to enroll 40 patients and has a registrational design [7] - Interim results from this trial were previously presented at ASCO 2025, indicating ongoing progress in the clinical evaluation of NXC-201 [7] Market Insights - The number of patients in the U.S. with relapsed/refractory AL Amyloidosis is projected to grow at a rate of 12% annually, reaching approximately 37,270 patients by 2025 [4] - The amyloidosis market was valued at $3.6 billion in 2017 and is expected to grow to $6 billion by 2025, reflecting significant market potential for treatments [5]